ReviewRenal failure2025
A new category for understanding the mechanisms of drug-induced kidney injury.
Review in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medications contribute to about a quarter of acute kidney injury (AKI) cases among patients in hospitals. The impact of AKI is substantial on both families and society, and it has become a worldwide public health concern. Recently, a new framework for drug-induced acute kidney injury (DI-AKI) classification has been proposed. According to this new framework, drugs are divided into four categories. Thus, we explain the mechanism thoroughly and give examples of drugs or drug categories linked to the classes in the new framework. Furthermore, a patient's condition may dynamically shift between categories. At the same time, we also took into account some susceptibility factors. These susceptibility factors may drive inter-class variation. The new classification system may shed new light on the mechanism of DI-AKI for clinicians and researchers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.